At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
Carboplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)
In Brief
A Phase 2 clinical trial evaluating Carboplatin and 3D-RT or IMRT for Breast Cancer. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedFeb 2011
Primary CompletionJul 2019
TodayJul 2026
First PostedFeb 3, 2011
Enrollment StartMar 6, 2009
Primary CompletionJul 8, 2019
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 15.4 years ago
Interventions
Carboplatindrug
IV, weekly for 6 weeks, AUC of 2.0
3D-RT or IMRTradiation
From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy